PE20181364A1 - Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4) - Google Patents

Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4)

Info

Publication number
PE20181364A1
PE20181364A1 PE2018000602A PE2018000602A PE20181364A1 PE 20181364 A1 PE20181364 A1 PE 20181364A1 PE 2018000602 A PE2018000602 A PE 2018000602A PE 2018000602 A PE2018000602 A PE 2018000602A PE 20181364 A1 PE20181364 A1 PE 20181364A1
Authority
PE
Peru
Prior art keywords
compositions
methods
histamine
receptor
treatment
Prior art date
Application number
PE2018000602A
Other languages
English (en)
Spanish (es)
Inventor
Zhijian Zhu
Helen Barker
Michael Yeadon
Wai Liu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20181364A1 publication Critical patent/PE20181364A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2018000602A 2015-10-26 2016-10-25 Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4) PE20181364A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562246482P 2015-10-26 2015-10-26
US201662329091P 2016-04-28 2016-04-28
US201662359066P 2016-07-06 2016-07-06

Publications (1)

Publication Number Publication Date
PE20181364A1 true PE20181364A1 (es) 2018-08-27

Family

ID=57200025

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000602A PE20181364A1 (es) 2015-10-26 2016-10-25 Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4)

Country Status (21)

Country Link
US (2) US20170158671A1 (https=)
EP (1) EP3368528A1 (https=)
JP (1) JP2018531288A (https=)
KR (1) KR20180067683A (https=)
CN (1) CN108602801A (https=)
AU (2) AU2016344627B9 (https=)
BR (1) BR112018007765A2 (https=)
CA (1) CA3001636A1 (https=)
CL (1) CL2018001092A1 (https=)
CO (1) CO2018004323A2 (https=)
EC (1) ECSP18038867A (https=)
HK (1) HK1252050A1 (https=)
IL (1) IL258813A (https=)
MX (1) MX2018005140A (https=)
PE (1) PE20181364A1 (https=)
PH (1) PH12018500822A1 (https=)
RU (1) RU2018119104A (https=)
SG (1) SG11201802676QA (https=)
TW (1) TW201729810A (https=)
WO (1) WO2017072131A1 (https=)
ZA (1) ZA201802183B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
RU2020111694A (ru) * 2017-10-09 2021-11-12 Тева Фармасьютикал Индастриз Лтд. Новые соли и твердые формы эсциталопрама
WO2019118921A1 (en) 2017-12-14 2019-06-20 Flodesign Sonics, Inc. Acoustic transducer drive and controller
JP2024506384A (ja) 2021-02-10 2024-02-13 イオリクス セラピューティクス,インコーポレーテッド ロフルミラストの眼科的送達方法
CA3231766A1 (en) 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002072548A2 (en) 2001-03-09 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
EP1543011B1 (en) 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
KR101235116B1 (ko) * 2005-10-17 2013-02-20 에스케이케미칼주식회사 광학활성 암로디핀 겐티세이트 염의 제조방법
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
JP2008127359A (ja) * 2006-11-22 2008-06-05 Kowa Co アトピー性皮膚炎の予防及び/又は治療剤
EP3378476A1 (en) * 2012-06-08 2018-09-26 Sensorion H4 receptor inhibitors for treating tinnitus

Also Published As

Publication number Publication date
AU2020200840A1 (en) 2020-02-27
CA3001636A1 (en) 2017-05-04
RU2018119104A (ru) 2019-11-28
CL2018001092A1 (es) 2018-08-10
BR112018007765A2 (pt) 2018-10-23
SG11201802676QA (en) 2018-05-30
AU2016344627B2 (en) 2019-11-07
HK1252050A1 (zh) 2019-05-10
ZA201802183B (en) 2019-02-27
RU2018119104A3 (https=) 2020-02-19
WO2017072131A1 (en) 2017-05-04
EP3368528A1 (en) 2018-09-05
KR20180067683A (ko) 2018-06-20
AU2016344627B9 (en) 2019-11-28
ECSP18038867A (es) 2018-05-31
MX2018005140A (es) 2018-05-07
CO2018004323A2 (es) 2018-07-19
CN108602801A (zh) 2018-09-28
AU2016344627A1 (en) 2018-05-10
JP2018531288A (ja) 2018-10-25
TW201729810A (zh) 2017-09-01
IL258813A (en) 2018-06-28
US20190135787A1 (en) 2019-05-09
PH12018500822A1 (en) 2018-10-01
US20170158671A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
PE20181364A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4)
NI200900159A (es) Moduladores de 2-aminopirimidina del receptor de histamina h4.
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
BR112017015310A8 (pt) uso de pgr4 como um agente anti-inflamatório
CO2018000113A2 (es) Compuestos derivados de 2-(4-fenil-2-oxopiridin-1-(2h)-il)alcanoilamina
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
CR20150476A (es) Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
PH12015501648B1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
NI201000214A (es) Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4.
GT201500243A (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX376164B (es) Composiciones y metodos para tratar el insomnio.
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2017005283A (es) Nuevos derivados de pirazol en calidad de inhibidores de la cinasa inductora de nf-kb (nik).
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
PE20170313A1 (es) Formulacion de ceritinib
AR106577A1 (es) Composiciones de pirimidina, composiciones ultrapuras y sus sales, sus métodos de preparación y sus métodos de uso para el tratamiento de enfermedades y condiciones mediadas por el receptor de histamina h4 (h4)
NI201500168A (es) Benzoxazoles sustituidos
UY33223A (es) Composiciones mucoadherentes y sus usos
WO2015191635A3 (en) Xanthine oxidase inhibitors and methods of use